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Abstract 
Heart disease is the leading cause of death in the United States and in Texas. Hyperlipidemia is a 
precursor to cardiovascular disease and is a highly manageable and treatable acute and chronic 
disease in the outpatient primary care setting. This project is designed to increase clinicians’ 
adherence to the American College of Cardiology/American Heart Association (2013) and 
American Diabetes Association (2016) clinical practice guidelines for the prevention of heart 
disease in 40 to 75 year old adults with type II diabetes through interactive education, an 
electronic alert, and quality improvement sessions on the treatment and management of 
cholesterol in a primary care setting. The objectives were to initiate assessment of atherosclerotic 
cardiovascular disease risk scores, improve diet/exercise counseling, and increase use of statin 
therapy when applicable. Key activities included interactive meetings, open discussions with 
staff, resources including the guidelines, and weekly performance emails. The electronic alert 
was implemented as a reminder to assess the target group. Three outcomes were analyzed. 
Atherosclerotic Cardiovascular Disease risk score assessment increased from 0% to 76.7%, diet 
and exercise counseling documentation increased from 85% to 100%, and statin therapy 
application increased from 55.1% to 72.2% in eligible adults 40 to 75 years old with type II 
diabetes. The interventions were successful in improving clinician adherence to the clinical 
practice guidelines. This initiative helps to build the body of evidence regarding useful 
interventions to improve primary prevention of heart disease by improving provider adherence to 
the clinical care guidelines for 40 to 75 year old adults with type II diabetes. 
Keywords: clinician adherence, type II diabetes, hyperlipidemia, heart disease, clinical practice 
guidelines  
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Heart disease is the leading cause of death in the United States and in Texas (Department 
of State Health Services [TDSHS], 2013). Hyperlipidemia and increased low density lipoproteins 
(LDL) are major risk factors and precursors to atherosclerosis and endothelial damage leading to 
cardiovascular disease (CVD) and stroke (Mozaffarian et al., 2014). Hyperlipidemia affected 
four of ten Texas adults in 2009 (DSHS, 2013) and is a highly manageable condition in the 
primary care setting.  
Adults with type II diabetes are at an increased risk for cardiovascular morbidity and 
mortality when compared to adults without diabetes. Randomized control trials have 
demonstrated that this risk can be assessed and found that 40 to 75 year old adults with type II 
diabetes, with LDL-C levels between 70-189 mg/dL can benefit from statin therapy as a means 
of primary prevention of cardiovascular disease. Effective interventions to promote evidence-
based practice for cardiac risk assessment while strengthening diet/exercise counseling are 
needed to improve primary prevention of heart disease in adults with diabetes. 
Statement of the Problem 
Adults with diabetes are two to four times more likely to develop heart disease or stroke 
than adults without diabetes (Mozaffarian et al., 2015). Cardiovascular Disease (CVD) is the 
leading cause of morbidity and mortality for adults with diabetes. In adults 65 or older, 68% of 
adults with diabetes die of CVD, with 16% dying from stroke (Mozaffarian et al., 2015). The 
presence of elevated plasma levels of the lipid cholesterol leads to an inflammatory process 
called atherosclerosis (McCance, 2014).  Atherosclerosis is a pathological process which affects 
various vascular systems in the body that can vary in symptom and severity (McCance, 2014). 
Innate and adaptive immune responses are contributors in the development of atherosclerosis. 
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This inflammatory response leads to endothelial damage and to the formation of plaque within 
the cardiovascular system, which can lead to heart attacks and strokes (McCance, 2014).  
The most up-to-date clinical practice guidelines for lipid management are the American 
College of Cardiology/American Heart Association (ACC/AHA) (2013) (Stone et al., 2014) and 
the American Diabetes Association (ADA) (2016). These guidelines highlight the importance of 
treating hyperlipidemia in adults with diabetes using a risk score to assess cardiovascular risk, 
prescribing the appropriate strength of statin therapy, and reinforcing dietary/exercise 
counseling.  
There is a paucity of studies demonstrating methods to improve primary care practice 
adherence to the ACC/AHA (2013) and/or ADA (2016) guidelines. It is imperative for clinicians 
to understand and implement these guidelines in order to decrease cardiovascular risk, morbidity, 
and mortality among type II adults with diabetes.  
Background and Significance  
CVD refers to a group of diseases that target the heart and blood vessels. Common forms 
of CVD include high blood pressure, stroke, coronary heart disease, and congestive heart failure 
(CHF) (DSHS, 2013). The Texas Department of State Health Services (TDSHS, 2013) estimated 
that 30.5% of all 2010 deaths in Texas were attributed to CVD. In 2010, hospitalization costs for 
CAD and CVD approached $20 billion, resulting in a financial burden for Texas (DSHS, 2013).  
 The first of two clinical practice guidelines available for the treatment of dyslipidemia in 
adults with type II diabetes are the ACC/AHA guidelines published in November 2013. The 
ACC/AHA (2013) state that 40 to 75 year old patients with diabetes should be assessed with the 
ASCVD risk calculator available online or through a phone application. Following the risk 
assessment, a moderate to high intensity statin therapy is recommended, in addition to diet and 
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exercise counseling to lower cardiovascular risk. The ADA clinical practice guidelines were 
published in January 2016 after an update to align with the clinical practice guidelines of the 
ACC/AHA (2013). The ADA (2016) guidelines reinforce the recommendations of the 
ACC/AHA (2013) guidelines in treatment of dyslipidemia by using the risk score, medication 
therapy, and reinforcing diet and exercise patient counseling in 40 to 75 year old adults with type 
II diabetes.  
The primary goal of the guidelines is lowering blood cholesterol in at-risk groups based 
on the current evidence supporting the ACC/AHA (2013) guidelines (Smith, & Grundy, 2014). 
The use of statin therapy with diet and regular exercise is indicated as primary prevention in 
accordance with the ACC/AHA (2013) and ADA (2016) guidelines for adults with diabetes who 
are 40 to 75 years old with LDL-C levels of 70-189 mg/dL. The assessment of ASCVD risk is 
recommended by the ACC/AHA (2013) in order to guide the intensity of statin treatment and 
direct provider discussion of patient risk for heart attacks and strokes.  
The guidelines state that adults 40 to 75 years old with type II diabetes with an LDL-C 
level of 70-189 mg/dL benefit from the use of statin therapy. The use of the ASCVD risk 
calculator aids in application of moderate to high intensity statin therapy based on risk. Adults 
with type II diabetes, LDL-C levels of 70-189 mg, and with an ASCVD risk greater or equal to 
7.5% qualify for high statin therapy. Adults with less than 7.5% ASCVD risk qualify for 
moderate statin therapy. The current guidelines aid the clinician in determining the risk score and 
application of moderate to high statin therapy for this at-risk population. The ACC/AHA (2013) 
guidelines continue to reinforce adherence to a healthy lifestyle through diet and exercise. The 
recommendations are for patients to eat a heart healthy diet, increase vegetable intake, legumes, 
and fiber, reduce consumption of red meats, and sweetened beverages (ACC/AHA, 2013). 
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Adults should engage regularly in 30-40 minutes of physical exercise, maintain a healthy body 
weight, and avoid tobacco products to decrease LDL-C levels (ACC/AHA, 2013).  
Assessment 
An independent primary care clinic in south central Texas was selected as the project site. 
The clinic is open Monday through Friday, and for a half day every other Saturday. Providers 
include one physician and three physician assistants. In a 12-month period from August 1, 2014 
to July 31, 2015 the clinic lists 16,596 established patients with 670 new patients seen annually. 
Individuals of Hispanic ethnicity compose the majority of the patient population. Patient 
demographics are depicted in Table 1. The clinic accepts 22 different insurance payers with the 
top four insurances billed being Blue Cross Blue Shield (25.4%), United HealthCare (17.4%), 
Medicare/Private (16%), and Medicare (5.4%). In general, patients have chronic conditions that 
include diabetes type II, hyperlipidemia, hypertension, asthma, and other conditions that require 
close monitoring by a primary care provider (PCP).  
Table 1  
Age Demographics 
Age Range  % of Patients Seen 
≥ 12 years old  4 
13-18 years old  7 
19-44 years old  45 
45-65 years old  46 
66 and older  8 
 
 
PRIMARY PREVENTION OF HEART DISEASE 10  
Pre-Intervention Assessment 
Sixty nine medical records were audited for patients with diabetes 40 to 75 years old 
without complications for adherence to the clinical guidelines including ASCVD risk 
assessment, diet/exercise counseling documentation, and statin therapy. Data collected included 
age, date of visit, lipids, blood pressure, BMI, HbA1c, statin therapy, statin strength, and 
documentation of diet/exercise counseling. Of the 69 charts reviewed there were no ASCVD risk 
scores documented. Of the 69 reviewed charts, 85.5% (59) had documentation of diet/exercise 
counseling while 14.5% (10) did not. From the 69 charts audited, 55.1% (38) of the patients were 
on statin therapy, 23.2% (16) were not receiving statin therapy, and 21.7% (15) were excluded 
because the LDL-C levels were 69 mg/dL or less.  
The analysis of the records demonstrated that Atherosclerotic Cardiovascular Disease 
(ASCVD) risk assessments were not being documented and verbal review verified that they were 
not being performed. Improvement in diet/exercise counseling was needed, as 15% of the 
patients had no documentation of counseling. The review also demonstrated decreased statin 
therapy application for patients who were eligible for statin therapy and were 40 to 75 years old 
with an LDL-C of  ≤ 100 mg/dL. 
Organizational Readiness  
The results of the medical records review were shared with the clinicians. The clinic is an 
active participant in quality improvement activities including participating in the Accountable 
Care Organization (ACO) program. Through the ACO program, the clinic works to provide high 
quality care to Medicare recipients and, if sufficiently demonstrated, receives a percentage of 
costs saved by the Centers for Medicare and Medicaid Services. The clinic also participates in 
the Health Care Incentive Improvement Institute (HCI3) Quality Improvement program by 
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voluntarily participating in the HCI3 “Bridge to Excellence Program” (Healthcare Incentives, 
2015) in which clinicians work to improve care measures in diabetes, cardiac care, and asthma 
care. The clinic receives monetary incentives to report and improve the care metrics of these 
patients. The clinicians actively participate in these evidence-based practice initiatives to 
improve the quality of care provided to patients. As a part of these initiatives, clinicians 
participate in meetings to review performance, discuss changes, and plan effective 
implementation. The clinic demonstrates adaptability to change and quality improvement.  
Project Identification 
Purpose 
The purpose of this project was to increase clinician adherence to the ACC/AHA (2013) 
and ADA (2016) clinical practice guidelines for the treatment and management of dyslipidemia 
in 40 to 75 year old patients with diabetes by providing an education/discussion session for 
clinicians, implementing an electronic medical record alert, and providing clinician resources for 
decision making in a primary care setting. The guidelines emphasize ASCVD risk screening, 
diet/exercise counseling, and medication therapy. The ACC/AHA (2013) risk tool will be used to 
determine a 10-year cardiac risk for cardiovascular disease per guideline recommendations 
(Stone et al., 2014).  
Objectives  
The objectives for the project are as follows: 
1. Within 10 weeks of project implementation, 50% of 40 to 75 year old patients with type 
II diabetes seen at the clinic will be assessed using the cardiovascular risk calculator once 
every five years in accordance with the ACC/AHA (2013) guidelines.  
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2. Within 10 weeks of project implementation, 90% of 40 to 75 year old adults with type II 
diabetes seen at the clinic will have diet and exercise counseling documented in their 
charts by the clinicians.  
3. Within 10 weeks of project implementation, 83% of 40 to 75 year old adults with type II 
diabetes and LDL-C levels above 70mg/dL seen at the clinic will be treated with statin 
therapy as a method of primary prevention for ASCVD in accordance with the 
ACC/AHA (2013) and ADA (2016) guidelines.  
Table 2 
Objectives and Anticipated Outcomes 
 
 
 
Objectives Outcomes Anticipated Outcomes 
1. 40 to 75 year old adults with 
type II diabetes will have their 
atherosclerotic cardiovascular 
disease (ASCVD) risk assessed.  
Assess ASCVD risk in target 
group 
(Chart review) 
Increase percent 
assessed from 0% to 
50%. 
2. 40 to 75 year old adults with 
type II diabetes will have diet and 
exercise counseling documented 
in their charts.  
Increase in diet and exercise 
counseling documentation in 
target group (Chart review) 
Increase percent 
counseled from 85% to 
90%. 
3. 40 to 75 year old adults with 
type II diabetes will be treated 
with statin therapy, if applicable. 
Increase in the use of statin 
medication therapy in target 
group (Chart Review). 
Increase percent treated 
from 51% to 83%. 
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Anticipated Outcomes  
The clinic will increase the use and documentation of the ASCVD risk assessment in 40 
to 75 year old adults with type II diabetes from 0% to 50% per ACC/AHA (2013) by using the 
risk tool for eligible patients. The clinic will improve and reinforce diet and exercise counseling 
of all 40 to 75 year old adults with type II diabetes from 85% to 90%. The clinic will increase the 
use of statin therapy, when applicable, from 51% to 83% in 40 to 75 year old adults with type II 
diabetes.  
Summary and Strength of the Evidence 
Adults with diabetes are two to four times more likely to have heart disease or stroke than 
adults without diabetes (AHA, 2016). The ADA (2016) considers diabetes to be a modifiable risk 
factor along with obesity, high cholesterol, lack of physical activity, and high blood pressure. 
Despite the well-established evidence between diabetes and the development of heart disease, 
minimal evidence exists in the literature regarding evidence-based practice for heart disease 
prevention in adults with type II diabetes. A search of the literature for the years 2013-2016 
demonstrated no published studies of interventions used to target adherence to the evidence-
based practices in the ACC/AHA (2013) guidelines. Practice implications of the ACC/AHA 
(2013) guidelines are not known. Studies are available regarding interventions used to increase 
adherence to the ADA standards of care regarding annual microalbumin screening, annual foot 
screening, and diabetic kidney disease knowledge (Anabtawi, 2013; Thompson-Martin, 
McCullough, & Agrawal, 2015; Umar-Kamara & Adams, 2013). The literature demonstrated 
that a multifaceted approach was an effective method to improve practice.  
Clinician Education  
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 Two studies demonstrated the effectiveness of educational sessions to improve adherence 
to standard guidelines. Lozman, Belcher, and Sloand (2013) conducted a quality improvement 
study in which a 30-minute education session in a primary pediatric clinic resulted in significant 
outcomes toward achieving the goal of reducing Papanicolaou screening according to the 
American Academy of Obstetrics and Gynecology pediatric guidelines. The education resulted in 
a reduction in Pappanicolau testing aligning with the guideline recommendations for the 
pediatric population (Lozman et al., 2013).  
A comparable study performed an education session as an intervention to improve 
adherence to obesity guidelines. The study by Barnes, Theeke, and Mallow (2015) implemented 
a bundle of interventions that included an education session, provider resources for patient 
education, a provider reminder, and used provider feedback to improve practice adherence to 
clinical practice guidelines (CPG). The methodology used to evaluate pre and post intervention 
outcomes was a review of the electronic medical record. The results of the study demonstrated 
no significant increase in diagnosis and patient management with body mass index (BMI) greater 
than or equal to 30 (Barnes et al., 2015). However, there was a 13% increase of height, weight, 
and BMI recording by the medical assistants (Barnes et al., 2015). 
Electronic Medical Record Alert   
A study by Gill, Chen, Glutting, Diamond, and Lieberman (2009) used an electronic 
decision alert for patients whose LDL-C was not at goal and for patients due for lipid laboratory 
tests. The alert was used to improve hyperlipidemia management and other chronic conditions, 
which resulted in slight improvements. The study explored the use of lipid management tools in 
the EMR for adherence to the Adult Treatment Panel III (ATP III) guidelines, however the study 
noted slight improvement in quality of lipid management after implementing the EMR reminder 
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in the primary care setting (Gill et al., 2009). The study did state that the EMR reminder might 
be useful to set up clinical reminders and reinforce adherence to CPG recommendations. Gill et 
al. (2009) suggested that electronic reminders and other quality measures would only have a 
modest impact until financial incentives for improved performance are offered. This study 
speaks to the impact of pay per performance reimbursement, which was implemented in Britain 
(Gill et al., 2009), and is currently a health model adopted by the affordable health care act. 
Recent reimbursement, incentives, and penalties from Centers for Medicare and Medicaid 
programs are encouraging providers to meet patient quality metrics.  
Clinician Resources  
Barnes et al. (2015) utilized a variety of methods to improve CPG adherence with 
education sessions, provider resources, a reminder system, and provider feedback, to improve 
team adherence to national obesity practice guideline. A Body Mass Index (BMI) poster on top 
of the scales served as a visual reminder to adhere to BMI assessment. Clinicians were given a 
patient education packet and a one-page summary form recommended by the National Institutes 
of Health to assess patient readiness to lose weight (Barnes et al., 2015). At mid-point, feedback 
on performance was provided to the staff and providers (Barnes et al., 2015). Medical assistants 
increased BMI documentation by 13%, which was significant (p < 0.01) (Barnes et al., 2015). 
The number of charts with BMIs of 30 or higher with a documented obesity diagnosis increased 
from two (pre-intervention) to four (post-intervention), a finding which was not significant. 
Documentation of weight loss increased from two to six. The intervention methodology used in 
this study demonstrated that educational resources, clinician feedback, and a reminder alert have 
the potential to be beneficial interventions.  
 
PRIMARY PREVENTION OF HEART DISEASE 16  
Methods 
A pre-intervention medical records review was performed on April 15, 2016 through 
April 30, 2016, for patient encounters with a diagnosis code of E11.9 (type II diabetes without 
complications) from December 1, 2015 to March 1, 2016. A total of 69 charts were reviewed. 
Data showed that 43.5% (30) were males and 56.5% (39) were females. From this group, 97.1% 
(67) were of Hispanic descent and 2.9% (2) were non-Hispanic ethnicity. Data analysis 
demonstrated that for 40 to 75 adults with type II diabetes with LDL-C ≥ 70 mg/dL, 55% of 69 
patients were on statin therapy in accordance with the guideline recommendations. Only 85% of 
the patient records screened had documented diet/exercise counseling. No ASCVD risk 
assessment was documented in the records screened for the target population. Three 
interventions were selected to drive guideline adherence. The first intervention was to provide an 
educational session for the clinicians and adjunct staff. The second intervention included 
building a customized EMR alert with recommendations to assess ASCVD and apply statin 
therapy for adults 40 to 75 years old with type II diabetes. The third intervention included 
coordinating three QI meetings with the clinicians to address barriers, suggestions, and make 
appropriate changes.  
Education Session  
The education intervention took place on June 6, 2016. The ADA (2016) and the 
ACC/AHA (2013) guidelines were reviewed with the clinicians for the target population of 40 to 
75 year old adults with type II diabetes. The patient diet/exercise counseling handout was 
discussed during the education session. This handout reinforces clinicians’ verbal counseling of 
the importance of adhering to a heart healthy diet and 40 minutes of physical exercise. The 
handout was to be given to hyperlipidemia care patients (Appendix A). The guidelines were 
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printed and emailed to the clinicians for future use and as a reference. On June 20 and June 21, 
2016 the scribes were trained on how to use and document ASCVD risk scores.  
EMR Intervention 
An EMR alert was created under the EMR health guideline features. The EMR alert was 
designed to activate for patients 40 to 75 years old with diabetic codes E11.9 type II diabetes 
mellitus without complications, E11.21 type II diabetes mellitus with diabetic nephropathy, 
E11.40 type II diabetes mellitus with diabetic neuropathy unspecified, and E11.65 type II 
diabetes mellitus with hyperglycemia. The EMR alert acted as a reminder system for the 
clinicians to follow through with recommendations based on the target group, 40 to 75 year old 
adults with type II diabetes. The alert would appear when a patient encounter was opened and no 
ASCVD risk documentation was found. The alert was set as a reminder to assess ASCVD risk if 
it had not been performed for the patient within the last 5 years and to consider the need for 
adjustment in exercise/diet or statin therapy.  
Clinician Resources  
A clinician resource was provided, which summarizes the ACC/AHA CPG (2013) (Cupp, 
2014) in a format that is easy for clinicians to read, follow, and use. In addition, the ADA (2016) 
summary CPG was provided and emailed to the clinicians. 
Quality Meetings and Incentive  
Following implementation, the clinicians were asked to participate in three quality improvement 
meetings. Meeting one was held one week after implementation and addressed clinician concerns 
with adherence. Patient handouts were provided. Meeting two was held 4 weeks after 
implementation and addressed clinician recommendations. Additional copies of the patient 
handouts were provided. Meeting three was held 10 weeks post implementation. At this time, the 
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student leader reviewed the clinic’s adherence and discussed the incorporation of processes into 
the clinic’s routine. As an incentive for participating in the project, taking time from their 
practice to attend quality improvement meetings, and working to determine the barriers and 
facilitators to guideline adherence, clinicians were awarded $100 for active participation in each 
quality improvement meeting. The incentive was sponsored by the Astellas Heart Health 
Through the Age Span Award (Appendix B). The clinic assessed the ASCVD risk score in 40 to 
75 year old adults with type II diabetes in all patients who needed laboratory work-up for chronic 
care and physical assessments. An educational handout was given to patients whose lipids were 
high and the clinicians provided reinforcement of diet and exercise counseling. This multifaceted 
intervention approach included an interactive educational discussion, an electronic alert, quality 
meetings, and clinician resources for decision-making for 40 to 75 year old adults with type II 
diabetes in this family practice. 
Two adjustments were made based on clinician feedback. The first was to assess ASCVD 
risk during physicals, and when patients came to the clinic for laboratory draws. The second was 
to only assess patients who were scheduled for chronic management/laboratory or physical 
exams. Assessing ASCVD risk for chronic care, laboratory results, or physical exams was 
practical for the clinic, and convenient for the patients as blood samples are collected in the 
clinic when fasting. This change, acknowledged by the student leader, assisted the clinicians to 
adhere to the implementation as it improved the clarity of which patients needed to be assessed. 
Organization Barriers and/or Facilitators 
Barriers to implementation of the clinical practice guidelines included identifying 
meeting times that accommodated clinician schedules. Performance in the beginning of 
implementation varied among clinicians with one clinician demonstrating lower guideline 
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adherence than others. ASCVD risk scores were calculated for patients who had a recent (within 
three months) lipid panel. Risk scores could not be calculated for patients whose total cholesterol 
was less than 130 mg/dL, and for patients whose systolic blood pressure was less than 90 mmHg.  
Facilitators included the presence of a quality improvement administrator who manages 
intervention and implementation changes based on quality measures established by payers. The 
use of established EMR software was helpful with creating an electronic alert for the clinic. The 
use of an EMR to collect data was a facilitator. Clinician and staff collaboration was essential to 
improve study objectives and adherence to guidelines. The incentive served as a facilitator to 
gain stakeholder support and become an active participant to implement changes based on 
weekly performance evaluations. This initiative demonstrated that team collaboration, 
stakeholder engagement, and the use of an incentive increased adherence to guidelines. 
Results 
Data collection 
A retrospective chart review was conducted post implementation between August 22, 
2016 and August 31, 2016. Charts were reviewed for all diabetic patients 40 to 75 years old seen 
from June 20, 2016 to August 26, 2016. The total number of charts reviewed post intervention 
was ninety. The same variables that were collected pre-intervention were collected post-
intervention. Variables included age, demographics, Medicare, blood pressure, lipid levels, 
HbA1c, aspirin use, body mass index, statin use, statin strength, clinician, and ASCVD risk 
assessment with score. During implementation, weekly reviews were conducted over the 10 
weeks to assess clinician adherence to ASCVD risk assessments. Three QI meetings were 
coordinated to identify barriers and facilitators, and provide a forum for clinician feedback.  
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Figure I depicts average clinician performance for ASCVD risk assessment throughout the 
implementation timeframe.  
Figure 1  
Average Clinician Performance for ASCVD Risk Assessment  
 
Data indicated that of the 90 patient charts reviewed, 42.2% (38) of the patients were 
males and 57.8 (52) were females; 97.8% (88) of the patients were of Hispanic ethnicity and 
2.2% (2) were non-Hispanic ethnicity.   
Objective 1:  Increase the ASCVD risk assessment from 0% to 50%.  The ASCVD risk 
assessment pre-intervention was 0% and rose to 76.7% (69) in the post intervention data. Only 
23.3% (21) of the patients were not screened with the ASCVD risk assessment. A Chi square 
demonstrated that among 40 to 75 year old adults with type II diabetes, there was a statistically 
significant relationship between pre and post intervention rates for ASCVD risk screening (߯2 
(1,159) = 93.46, p < .001).   
 
0%
20%
40%
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85%
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Table 3  
ASCVD Risk Assessment Pre and Post Intervention 
 
	
 
Pre-Intervention 
 
Post-Intervention 
 
Total		
Yes 
 
0 
 
69 
 
69 
No 
 
69 
 
21 
 
90 
Total 
 
69 
 
90 
 
159 
 
Objective 2: Increase diet and exercise counseling documentation from 85% to 90%. For 
objective number two, diet and exercise counseling rose to 100% (90), achieving more than the 
target goal of 90%. These were attributed to the constant feedback and reminder to counsel and 
document appropriately in the EMR. 
Among 40 to 75 year old adults with type II diabetes, there was a statistically significant 
relationship between pre and post intervention for diet and exercise counseling documentation 
(߯2 (1,159) = 21.60, p < .001). 
Table 4  
Diet and Exercise Counseling Documentation  
 Yes No Total 
Pre-Intervention  54 15 69 
Post-Intervention  90 0 90 
Total  144 15 159 
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Objective 3: Increase statin therapy when applicable for 40 to 75 years old adults with 
type II diabetes from 55% to 83%. For objective number three, statin therapy treatment improved 
from 55% to 72.2%. A Chi square revealed that among 40 to 75 year old adults with type II 
diabetes and LDL-C levels  70mg/dL, there was a statistically significant relationship between 
the intervention and the application of statin therapy (߯2 (1,159)=11.55, p = .003). 
Table 5  
Statin Use Pre & Post Intervention 
 
 
 
Pre-Intervention 
 
Post-Intervention 
 
Total 
Yes 
 
38 
 
65 
 
103 
No 
 
16 
 
21 
 
37 
Not Applicable 
 
15 
 
4 
 
19 
Total 
 
69 
 
90 
 
159 
 
A One-way ANOVA demonstrated that mean ASCVD Risk Score differed significantly 
between the age groups of 40 to 49, 50 to 59, and 60 to 75 (߭ (2, 65) = 35.014, p < .001). Post 
hoc comparisons using the Tukey HSD showed significant differences in the mean ASCVD Risk 
Score between the 40 to 49 age group and 60 to 75 age group (ܯ = 13.0, SE = 2.21, p < .001) 
and the 50 to 59 age group and the 60 to 75 age group (M = 12.9, SE=1.73, p < .001). However, 
there was no significant difference in the mean ASCVD Risk Score between the 40 to 49 age 
group, and the 50 to 59 age group (M = .06, SE = 2.36, p = 1.00). These findings reinforced the 
need for early intervention with diet/exercise lifestyle modifications, and statin therapy to 
decrease CVD risk later in life.  
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Figure 2  
ASCVD Risk Score Differences by Age Groups  
 
Discussion 
 The ASCVD risk score was assessed for all 40 to 75 year old adults coming to the clinic 
for their physical exam and/or laboratory workup. However, for the purpose of this project, data 
was collected only for 40 to 75 year old adults with type II diabetes. The clinicians were given 
weekly performance reviews, and the student leader conducted three quality improvement 
meetings to discuss barriers, changes, and clinician feedback. An electronic alert was used to 
reinforce changes and clinician resources for decision-making were given in hard copy and 
emailed. Two of three objectives were successfully met, and surpassed expectations. ASCVD 
risk screening increased from 0% to 77%, while diet and exercise counseling documentation 
increased from 85% to 100%. Statin therapy application increased significantly from 55.1% to 
72.2%, however did not achieve the goal to increase to 83%. There is no data or evidence in the 
literature to compare ASCVD risk screening rates to that of the clinic.  
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Clinician participation and adjunct staff participation in this QI initiative resulted in an 
increase in adherence to the ACC/AHA (2013) and ADA (2016) guidelines for lipid 
management. The interventions and objectives met provide a step forward towards 
implementation of evidence-based best practice recommendations by practice guidelines, as 
mandated both by the Institute of Medicine and current health care models to improve the care 
provided to 40 to 75 year old adult patients with type II diabetes. Progress was seen through the 
QI initiative for improving outcomes in adults with type II diabetes for primary prevention of 
heart disease in a family primary care setting when clinicians and adjunct staff participation 
resulted in adherence to the ACC/AHA (2013) and ADA (2016) guidelines for dyslipidemia 
management.  
Limitations 
Limitations included implementation timeframe, which impacted the number of charts 
reviewed post intervention to 90. Sample size pre intervention (69) and post intervention (90) 
was small. In addition, clinicians were absent due to maternity leave and vacation time during 
implementation. Ninety seven percent of the patients were of Hispanic origin, a factor that may 
limit the interpretation of this project with other populations.  
Recommendations 
The results of this QI initiative demonstrate the positive impact of multifaceted 
interventions to improve dyslipidemia patient care for adults with type II diabetes. The first 
recommendation is to engage clinicians by scheduling quality meetings and having open 
discussion for suggestions and improvement. Meetings serve to address barriers to change noted 
by the clinicians and project leader. It is important to stay attentive for Centers for Medicare and 
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Medicaid Services incentives to initiate similar initiatives in the clinic as incentives are a useful 
resource to increase stakeholder engagement. 
The use of an EMR alert, weekly performance measures, and patient education handouts, 
reinforce the continuation of the changes that need to take place to meet objectives. Weekly 
performance reports provide a tangible comparison of each clinician, thus incentivizing peers to 
perform equally. It is important to consider the use of computer technology, phone applications, 
and/or use of EMR alerts as reminders to reinforce practice changes. 
There is a need for literature contributions regarding ASCVD risk assessment and 
intervention methods used. ASCVD risk discussion between clinician and patient should be 
studied.  
Implications for Practice 
In 2011, the Institute of Medicine made a call to advance practice research DNP prepared 
nurses, to target the challenges discovered in the current provider driven, fragmented, volume 
based delivery of care, to a cost effective, coordinated, evidence based practice driven, value 
based care, needed to improve population health and quality outcomes (Kendall-Gallagher & 
Breslin, 2013; Zaccagini & White, 2014). The doctor of nursing practice (DNP) is a degree, but 
often with a practice role that prepares nurses to the highest level of education for practice 
application in the use of EBP to achieve patient positive outcomes, implement routine QI 
methods, and effectively improve adherence to changes (Zaccagini & White, 2014).  
This initiative demonstrated that team collaboration, stakeholder engagement, and the use 
of an incentive increased adherence to guidelines. The positive outcomes of this initiative 
indicate that APRNs can have an impact in practice and collaborate with an interdisciplinary 
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team. Primary care clinicians and APRNs can play a significant role in mitigating the negative 
cardiovascular risk outcomes found in adult patients with type II diabetes.  
Conclusion 
Cardiovascular disease remains the number one cause of death in the United States. It is 
important to assess ASCVD risk and initiate statin therapy for adults with type II diabetes whom 
are susceptible to heart attacks and strokes. It is imperative to begin the discussion of CVD risk 
with the population of adults who have diabetes and implement best practice methods to improve 
the quality of care provided to adults with type II diabetes. In a complex healthcare system, it is 
necessary to work collaboratively to achieve measured outcomes.  Incentives were a helpful 
resource to initiate, gain stakeholder interest, and sustain QI efforts. The APRN has the advanced 
training to bridge the gap between evidence to practice. Their expert knowledge and complex 
decision making skills are needed to translate the changing healthcare models to align evidence 
and practice.  
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May 16, 2016                                                                                     
         
Litzie Ramos BSN, RN 
6718 Callaghan Rd. # 202 
San Antonio, TX  78229 
 
Dear Litzie, 
 
The Nurse Practitioner Healthcare Foundation is pleased to inform you that you have been 
selected to receive a 2016 NPHF/Astellas Heart Health Through the Age Span Award for your 
project, “Diabetic Heart Disease Prevention. ” The award of $4000 total will provide support for 
your project and for disseminating your findings to enhance knowledge and practice. Your 
project, as well as your commitment to advancing heart health, are testimony to the impact that 
nurse practitioners have in shaping the health care system now and in the future.  
 
The award will be made in two payments: the first payment of $3000 to support project 
development and initiation, the second payment of $1000 provided at the end of the project for 
project dissemination (poster or podium presentation at a healthcare conference, journal article, 
etc. ). Please submit the enclosed W-9 now and your IRB approvals or exemptions no later than 
August 30, if they were pending or not submitted with your original application. Once we 
receive these, we will release the initial payment to you. We will require a progress report on 
your project by December 20, 2016 and a final report by June 30, 2017.  
 
The Nurse Practitioner Healthcare Foundation will prepare a press release for national 
publication and will announce the award on our website. Please provide a color photo headshot 
and a short bio-sketch no later than June 30 to pamjw@nphealthcarefoundation. org 
 
Appendix B 
PRIMARY PREVENTION OF HEART DISEASE 32  
Please remember that you have agreed to acknowledge the Nurse Practitioner Healthcare 
Foundation/Astellas Heart Health Through the Age Span Award Program in any clinical, 
educational or research publications, posters or presentations stemming from work done through 
this funding. Please notify us of all poster and podium presentations of your work and send us a 
copy of any publications from your research project. We will use your successes to help us gain 
support for future award programs.  
 
I will send required forms and agreements for your signature within the next two weeks. Please 
complete and return them by the deadline noted below. 
Our very best wishes for a successful and productive future as a nurse practitioner leader and, 
again, congratulations! 
 
Sincerely, 
 
 
 
 
 
Pam Jenkins-Wallace, MS, NP 
Program Director, NPHF 
pamjw@nphealthcarefoundation. org 
 
 
NPHF Program Office 
7592 Highland Oaks Dr.    Pleasanton, CA 94588 
925-989-5431 (Mobile- preferred) 925-461-1102 (Office) 
pamjw@nphealthcarefoundation. 
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